TRIM33 and neoplasm: Furthermore, we propose that anti-TIF-1γ antibodies might serve as a prognostic marker of worse clinical outcome in early breast cancer provided correlation between serum anti-TIF-1γ antibodies and TIF-1γ expression in the tumor is found.